Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polycyclic aromatic hydrocarbons (PAHs) are a large class of organic environmental pollutants consisting of two or more fused aromatic rings containing only carbon and hydrogen[1][5][9]. They are uncharged, nonpolar, hydrophobic molecules, usually found as solids that are relatively insoluble in water and have low volatility at room temperature[9]. PAHs are typically formed during incomplete combustion of organic materials, and they are widely distributed in the environment, present in fossil fuels and as contaminants in food, air, and water[4][9]. While PAHs are of intense biological and medical interest due to their toxicity, mutagenicity, and especially their role in carcinogenesis, they are not themselves therapeutic targets, enzymes, receptors, or proteins[1][5]. Rather, they act as ligands for certain biological receptors, most notably the aryl hydrocarbon receptor (AhR); interactions with AhR upregulate metabolic enzymes (e.g., cytochrome P450s) that metabolize PAHs to reactive, mutagenic intermediates[2][5][8]. Their toxic, carcinogenic, and immunomodulatory bioeffects are mediated both through receptor binding and direct interference with cellular structures and communication[5][6]. PAHs are notable for bioaccumulation—particularly in fat-rich tissues, breast milk, and the liver—and for their environmental persistence due to chemical stability and resistance to degradation[4][7][9]. Chronic human exposure to PAHs, especially to high-molecular-weight compounds like benzo[a]pyrene, is associated with increased risk of cancer, lung inflammation, and systemic toxicity[4][6]. Biomarkers such as 1-hydroxypyrene and 8-OHdG are used to monitor exposure and effects[8][6]. Due to their structure and properties, “polycyclic aromatic hydrocarbon” is not a therapeutic target, but rather a class of chemical toxicants. The query is incorrect in identifying PAH as a druggable target or biomolecule ("is_incorrect: true").
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polycyclic aromatic hydrocarbon (PAH).